TY - JOUR
T1 - Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner
AU - Bayik, Defne
AU - Zhou, Yadi
AU - Park, Chihyun
AU - Hong, Changjin
AU - Vail, Daniel
AU - Silver, Daniel J.
AU - Lauko, Adam
AU - Roversi, Gustavo
AU - Watson, Dionysios C.
AU - Lo, Alice
AU - Alban, Tyler J.
AU - McGraw, Mary
AU - Sorensen, Mia
AU - Grabowski, Matthew M.
AU - Otvos, Balint
AU - Vogelbaum, Michael A.
AU - Horbinski, Craig
AU - Kristensen, Bjarne Winther
AU - Khalil, Ahmad M.
AU - Hwang, Tae Hyun
AU - Ahluwalia, Manmeet S.
AU - Cheng, Feixiong
AU - Lathia, Justin D.
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020
Y1 - 2020
N2 - Myeloid-derived suppressor cells (MDSC) that block antitumor immunity are elevated in glioblastoma (GBM) patient blood and tumors. However, the distinct con-tributions of monocytic (mMDSC) versus granulocytic (gMDSC) subsets have yet to be determined. In mouse models of GBM, we observed that mMDSCs were enriched in the male tumors, whereas gMDSCs were elevated in the blood of females. Depletion of gMDSCs extended survival only in female mice. Using gene-expression signatures coupled with network medicine analysis, we demonstrated in preclinical models that mMDSCs could be targeted with antiproliferative agents in males, whereas gMDSC function could be inhibited by IL1β blockade in females. Analysis of patient data confirmed that proliferating mMDSCs were predominant in male tumors and that a high gMDSC/IL1β gene signature correlated with poor prognosis in female patients. These findings demonstrate that MDSC subsets differentially drive immune suppression in a sex-specific manner and can be leveraged for therapeutic intervention in GBM. SIGNIFICANCE: Sexual dimorphism at the level of MDSC subset prevalence, localization, and gene-expression profile constitutes a therapeutic opportunity. Our results indicate that chemotherapy can be used to target mMDSCs in males, whereas IL1 pathway inhibitors can provide benefit to females via inhibition of gMDSCs.
AB - Myeloid-derived suppressor cells (MDSC) that block antitumor immunity are elevated in glioblastoma (GBM) patient blood and tumors. However, the distinct con-tributions of monocytic (mMDSC) versus granulocytic (gMDSC) subsets have yet to be determined. In mouse models of GBM, we observed that mMDSCs were enriched in the male tumors, whereas gMDSCs were elevated in the blood of females. Depletion of gMDSCs extended survival only in female mice. Using gene-expression signatures coupled with network medicine analysis, we demonstrated in preclinical models that mMDSCs could be targeted with antiproliferative agents in males, whereas gMDSC function could be inhibited by IL1β blockade in females. Analysis of patient data confirmed that proliferating mMDSCs were predominant in male tumors and that a high gMDSC/IL1β gene signature correlated with poor prognosis in female patients. These findings demonstrate that MDSC subsets differentially drive immune suppression in a sex-specific manner and can be leveraged for therapeutic intervention in GBM. SIGNIFICANCE: Sexual dimorphism at the level of MDSC subset prevalence, localization, and gene-expression profile constitutes a therapeutic opportunity. Our results indicate that chemotherapy can be used to target mMDSCs in males, whereas IL1 pathway inhibitors can provide benefit to females via inhibition of gMDSCs.
UR - http://www.scopus.com/inward/record.url?scp=85086677163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086677163&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-19-1355
DO - 10.1158/2159-8290.CD-19-1355
M3 - Article
C2 - 32300059
AN - SCOPUS:85086677163
SN - 2159-8274
VL - 10
SP - 1210
EP - 1225
JO - Cancer discovery
JF - Cancer discovery
IS - 8
ER -